Back to Results

BioForce Nanosciences Holdings Inc (BFNH)

Featured in Overvalued Stocks

BioForce Nanosciences Holdings Inc. is a common stock listing on OTC Markets under the ticker BFNH. The company focuses on natural vitamins, minerals, nutritional supplements, powders, and beverages for consumers across different age groups. Its products are distributed through private-label arrangements with distributors and manufacturing partners, and the company also reaches customers through retailers, sporting goods stores, supermarkets, mass merchandisers, its website, social media, and telemarketing channels. BioForce Nanosciences Holdings is based in Virginia Beach, Virginia.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-BFNH
$0.84
-38.4% Downside
Overvalued
—
—
—
Fair
—
—
—
0.0%
August 18, 2026
-109.7x
-69.8x
—
50.324 M
50.417 M
0.2%
25.3%
-36,188.3
—
9.3%
Send a message
Valuation • Fair Value

BioForce Nanosciences Holdings Inc (OTC-BFNH) Fair Value by Valuation Model

Compare the primary fair value estimate for BioForce Nanosciences Holdings Inc (OTC-BFNH) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.84

Estimated downside of 38.4% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$0.84

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for BioForce Nanosciences Holdings Inc (OTC-BFNH) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for BioForce Nanosciences Holdings Inc (OTC-BFNH)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review BioForce Nanosciences Holdings Inc (OTC-BFNH) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for BioForce Nanosciences Holdings Inc (OTC-BFNH)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-36,188.3

Lower score that deserves closer risk review.

FCF / Net Income

9.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for BioForce Nanosciences Holdings Inc (OTC-BFNH). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for BioForce Nanosciences Holdings Inc (OTC-BFNH)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 18, 2026

Days to Earnings

28

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for BioForce Nanosciences Holdings Inc (OTC-BFNH), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

BioForce Nanosciences Holdings Inc (OTC-BFNH) Stock Forecast & Technical Outlook

Review BioForce Nanosciences Holdings Inc (OTC-BFNH) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for BioForce Nanosciences Holdings Inc (OTC-BFNH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for BioForce Nanosciences Holdings Inc (OTC-BFNH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for BioForce Nanosciences Holdings Inc (OTC-BFNH) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for BioForce Nanosciences Holdings Inc (OTC-BFNH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for BioForce Nanosciences Holdings Inc (OTC-BFNH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for BioForce Nanosciences Holdings Inc (OTC-BFNH)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for BioForce Nanosciences Holdings Inc (OTC-BFNH) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

BioForce Nanosciences Holdings Inc (OTC-BFNH) Stock FAQ

Quick answers about BioForce Nanosciences Holdings Inc (OTC-BFNH) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.84
Estimated downside 38.4%
Valuation Rating
Overvalued
Estimated downside of 38.4%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Fair
Current financial-health read

The current fair value estimate for BioForce Nanosciences Holdings Inc (OTC-BFNH) is $0.84. This implies an estimated downside of 38.4% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 38.4% versus the current market price.

An analyst price target for BioForce Nanosciences Holdings Inc (OTC-BFNH) is not currently available in the latest data file.

The current financial health read for BioForce Nanosciences Holdings Inc (OTC-BFNH) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for BioForce Nanosciences Holdings Inc (OTC-BFNH) is August 18, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for BioForce Nanosciences Holdings Inc (OTC-BFNH) is -109.7x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for BioForce Nanosciences Holdings Inc is 50.324 M.

The current enterprise value listed for BioForce Nanosciences Holdings Inc is 50.417 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for BioForce Nanosciences Holdings Inc is OTC-BFNH, and the stock is listed on OTC Markets.

BioForce Nanosciences Holdings Inc (OTC-BFNH) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for BioForce Nanosciences Holdings Inc is 0.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for BioForce Nanosciences Holdings Inc is 25.3%. Free float helps investors understand how much of the share base is available for public trading.

Similar Personal Care Products Stocks on OTC Markets View more

L’Oreal Co ADR (LRLCY) L’Oreal Co ADR (LRLCY)
Beiersdorf AG ADR (BDRFY) Beiersdorf AG ADR (BDRFY)
Kao Corp ADR (KAOOY) Kao Corp ADR (KAOOY)
Puig Brands SA ADR (PUGBY) Puig Brands SA ADR (PUGBY)
Shiseido Company Ltd (SSDOY) Shiseido Company Ltd (SSDOY)
Hengan International Group Company Ltd ADR (HEGIY) Hengan International Group Company Ltd ADR (HEGIY)
Hengan Intl Group Ltd-H (HEGIF) Hengan Intl Group Ltd-H (HEGIF)
Kose Corp ADR (KSRYY) Kose Corp ADR (KSRYY)
PZ Cussons PLC ADR (PZCUY) PZ Cussons PLC ADR (PZCUY)
Horizon Kinetics Holding Corp (HKHC) Horizon Kinetics Holding Corp (HKHC)
Ascend Wellness Holdings Inc (AAWH) Ascend Wellness Holdings Inc (AAWH)
Zivo Bioscience Inc (ZIVO) Zivo Bioscience Inc (ZIVO)
Healthy Extracts Inc (HYEX) Healthy Extracts Inc (HYEX)
Citrine Global Corp (CTGL) Citrine Global Corp (CTGL)
Glucose Health Inc (GLUC) Glucose Health Inc (GLUC)
Smart Trends Network Inc (STSN) Smart Trends Network Inc (STSN)
BioRegenx Inc (BRGX) BioRegenx Inc (BRGX)
Integrated Biopharma Inc (INBP) Integrated Biopharma Inc (INBP)
Cyanotech Corporation (CYAN) Cyanotech Corporation (CYAN)
CCA Industries Inc (CAWW) CCA Industries Inc (CAWW)
CV Sciences Inc (CVSI) CV Sciences Inc (CVSI)
Reliv International Inc (RELV) Reliv International Inc (RELV)
Redwood Scientific Technologies Inc (RSCI) Redwood Scientific Technologies Inc (RSCI)
Fuss Brands Corp (FBDS) Fuss Brands Corp (FBDS)